DDInter7 DDInter1676
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed after unsuccessful endocrine therapy. It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with. Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Abemaciclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Secobarbital
Abemaciclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Abemaciclib {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Abemaciclib {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital
Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Abemaciclib may lead to a major life threatening interaction when taken with Troleandomycin
Abemaciclib may lead to a major life threatening interaction when taken with Fingolimod